C. Difficile

August 29th 2024

A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.

August 27th 2024

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

August 26th 2024

In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.

August 23rd 2024

The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.